#### **ANNUAL BURDEN ESTIMATES**

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Final Tribal TANF Data Report	66 66 66	4 1 1	451 40 60	119,064 2,640 3,960
Estimated Total Annual Burden Hours				125,664

In compliance with the requirements of Section 506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. Email address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

#### Robert Sargis,

Reports Clearance Officer. [FR Doc. 2012–2882 Filed 2–7–12; 8:45 am]

BILLING CODE 4184-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

### Notice of Change in Application Requirements

**AGENCY:** Administration on Developmental Disabilities, ACF, HHS.

**ACTION:** Notification of change in allocation notification procedures to State Protection and Advocacy Systems (P&As) for mandatory awards under the Help America Vote Act (HAVA), Public Law 107–252.

CFDA Number: 93.617.

Statutory Authority: Title II, Subtitle D, Part 5, of HAVA 42 U.S.C. 15461–62; Section 102 of the Developmental Disabilities Assistance and Bill of Rights Act of 2000 (DD Act) (42 U.S.C. 15002); and Section 509 of the Rehabilitation Act of 1973 as amended (29 U.S.C. 794e)

SUMMARY: The Administration for Children and Families (ACF), Administration on Developmental Disabilities (ADD) has modified the application requirements for awards made to P&As under HAVA, Public Law 107–252. Under the program, formula grants are allotted to States based on population, financial need, and need for service. P&As provide services to individuals with developmental disabilities based on the identification of goals in the areas of emphasis listed in the DD Act and based on public input.

Section 291 of HAVA does not outline specific application requirements for P&As. Therefore, ADD has the discretion to alter the process by which P&As are notified of their annual allocations. Accordingly, P&As will no longer be required to submit an application; and, an annual Funding Opportunity Announcement (FOA) will no longer be published. Instead, ADD will now rely solely on the official notification provided to P&As by ACF's Division of Mandatory Grants. This notice informs P&As of the availability of their annual award allocations.

#### FOR FURTHER INFORMATION CONTACT:

Melvenia Wright, Program Specialist. Telephone: (202) 690–5557. Email: Melvenia.Wright@acf.hhs.gov.

Dated: February 2, 2012.

#### Sharon Lewis,

Commissioner, Administration on Developmental Disabilities.

[FR Doc. 2012–2920 Filed 2–7–12; 8:45 am]

BILLING CODE 4184-38-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **Food and Drug Administration**

[Docket No. FDA-2011-N-0827]

Agency Information Collection Activities; Proposed Collection; Comment Request; Revisions to Labeling Requirements for Blood and Blood Components, Including Source Plasma; Correction

**AGENCY:** Food and Drug Administration, HHS

**ACTION:** Notice; correction and extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal** Register of December 30, 2011. In the Federal Register of December 30, 2011, FDA published a notice entitled "Agency Information Collection Activities; Proposed Collection; Comment Request; Revisions to Labeling Requirements for Blood and Blood Components, Including Source Plasma," which provided incorrect publication information regarding the availability of the final rule. This document corrects this error and extends the comment period. Elsewhere in this issue of the Federal Register, FDA is publishing a companion final rule correction notice.

#### FOR FURTHER INFORMATION CONTACT:

Joyce Strong, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, Silver Spring, MD 20993–0002, 301– 796–9148. **SUPPLEMENTARY INFORMATION:** In FR Doc. 2011–33555, appearing on page 82300 in the **Federal Register** of Friday, December 30, 2011 (76 FR 82300), the following corrections are made:

- 1. On page 82300, in the third column, in the **DATES** section, the submission date for comments should be corrected to "April 9, 2012". We are extending the comment period from February 28, 2012, to 60 days after this correction notice publishes to allow the public sufficient time to comment.
- 2. On page 82301, in the first column, in the second full paragraph in the SUPPLEMENTARY INFORMATION section, the last sentence is corrected to read: "This document solicits comments on certain labeling requirements for blood and blood components, including Source Plasma, finalized as part of a rule FDA published on January 3, 2012, entitled 'Revisions to Labeling Requirements for Blood and Blood Components, Including Source Plasma." We are making this change because the final rule inadvertently did not publish on December 30, 2011.

Dated: February 2, 2012.

#### Leslie Kux,

Acting Assistant Commissioner for Policy. [FR Doc. 2012–2827 Filed 2–7–12; 8:45 am]

BILLING CODE 4160-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2012-N-0001]

**Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** 

**AGENCY:** Food and Drug Administration,

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Endocrinologic and Metabolic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the Agency on FDA's regulatory issues.

Date and Time: The meeting will be held on March 28 and 29, 2012 from 8 a.m. to 5 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993–0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

Contact Person: Paul Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, (301) 796-9001, Fax: (301) 847-8533, email: EMDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1 (800) 741–8138 (301) 443–0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda: On both days, the committee will discuss the role of cardiovascular assessment in the preapproval and postapproval settings for drugs and biologics developed for the treatment of obesity.

FDÅ intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <a href="http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm">http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm</a>. Scroll down to the appropriate advisory committee link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 14, 2012. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 10 a.m. on March 29, 2012. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of

proposed participants, and an indication of the approximate time requested to make their presentation on or before March 6, 2012. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 7, 2012.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing

access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Paul Tran at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 2, 2012.

#### Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2012–2760 Filed 2–7–12; 8:45 am]

BILLING CODE 4160-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. FDA-2012-N-0067]

# Assessment of Analgesic Treatment of Chronic Pain—A Public Workshop; Request for Comments

**AGENCY:** Food and Drug Administration. **ACTION:** Notice of public workshop; request for comments.

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), is announcing a public workshop to hear a discussion of the available data on the efficacy of analgesics in the treatment of chronic non-cancer pain (CNCP). The focus of the presentations and discussions by scientific experts and other stakeholder